
EquitySector - HealthcareVery High Risk
Regular
NAV (30-Oct-25)
Returns (Since Inception)
Fund Size
₹443 Cr
Expense Ratio
2.38%
ISIN
INF03VN01878
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+9.98%
+3.67% (Cat Avg.)
Since Inception
+22.24%
— (Cat Avg.)
| Equity | ₹394.28 Cr | 89.07% |
| Others | ₹48.4 Cr | 10.93% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹31.55 Cr | 7.13% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹30.71 Cr | 6.94% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹30.14 Cr | 6.81% |
| Fortis Healthcare Ltd | Equity | ₹29.6 Cr | 6.69% |
| Cipla Ltd | Equity | ₹20.17 Cr | 4.56% |
| Laurus Labs Ltd | Equity | ₹18.96 Cr | 4.28% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹18.1 Cr | 4.09% |
| Neuland Laboratories Ltd | Equity | ₹14.16 Cr | 3.20% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹14.1 Cr | 3.19% |
| Lupin Ltd | Equity | ₹13.89 Cr | 3.14% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹13.5 Cr | 3.05% |
| Sai Life Sciences Ltd | Equity | ₹12.79 Cr | 2.89% |
| Divi's Laboratories Ltd | Equity | ₹12.28 Cr | 2.77% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹10.97 Cr | 2.48% |
| Abbott India Ltd | Equity | ₹9.47 Cr | 2.14% |
| Gland Pharma Ltd | Equity | ₹8.58 Cr | 1.94% |
| Shaily Engineering Plastics Ltd | Equity | ₹8.44 Cr | 1.91% |
| Ajanta Pharma Ltd | Equity | ₹7.76 Cr | 1.75% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹7.33 Cr | 1.66% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹7.3 Cr | 1.65% |
| Mankind Pharma Ltd | Equity | ₹7.28 Cr | 1.64% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹7.12 Cr | 1.61% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹6.97 Cr | 1.58% |
| Anthem Biosciences Ltd | Equity | ₹6.68 Cr | 1.51% |
| Pfizer Ltd | Equity | ₹6.63 Cr | 1.50% |
| AstraZeneca Pharma India Ltd | Equity | ₹6.55 Cr | 1.48% |
| Alembic Pharmaceuticals Ltd | Equity | ₹6.19 Cr | 1.40% |
| Emcure Pharmaceuticals Ltd | Equity | ₹6.01 Cr | 1.36% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹5.28 Cr | 1.19% |
| Thyrocare Technologies Ltd | Equity | ₹5.27 Cr | 1.19% |
| Treasury Bills | Bond - Gov't/Treasury | ₹5 Cr | 1.13% |
| 364 DTB 18122025 | Bond - Gov't/Treasury | ₹4.94 Cr | 1.12% |
| Poly Medicure Ltd | Equity | ₹4.56 Cr | 1.03% |
| Net Receivables / (Payables) | Cash - Collateral | ₹-4.31 Cr | 0.97% |
| Acutaas Chemicals Ltd | Equity | ₹4.15 Cr | 0.94% |
| HealthCare Global Enterprises Ltd | Equity | ₹3.54 Cr | 0.80% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹3.51 Cr | 0.79% |
| Supriya Lifescience Ltd | Equity | ₹3.48 Cr | 0.79% |
| Navin Fluorine International Ltd | Equity | ₹3.33 Cr | 0.75% |
| Shilpa Medicare Ltd | Equity | ₹3.11 Cr | 0.70% |
| 182 Days Tbill Red 28-05-2026 | Bond - Gov't/Treasury | ₹2.96 Cr | 0.67% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹2.55 Cr | 0.58% |
| Zota Health Care Ltd | Equity | ₹2.49 Cr | 0.56% |
| Piramal Pharma Ltd | Equity | ₹2.27 Cr | 0.51% |
| PB Fintech Ltd | Equity | ₹2.24 Cr | 0.50% |
| Jubilant Ingrevia Ltd Ordinary Shares | Equity | ₹2.02 Cr | 0.46% |
| 364 DTB 03102025 | Bond - Gov't/Treasury | ₹2 Cr | 0.45% |
| Orchid Pharma Ltd | Equity | ₹1.99 Cr | 0.45% |
| 91 Days Tbill (Md 04/12/2025) | Bond - Gov't/Treasury | ₹1.98 Cr | 0.45% |
| OneSource Specialty Pharma Ltd | Equity | ₹1.87 Cr | 0.42% |
| 91 Days Tbill Red 30-10-2025 | Bond - Gov't/Treasury | ₹1.19 Cr | 0.27% |
| 91 Days Tbill (Md 20/11/2025) | Bond - Gov't/Treasury | ₹0.99 Cr | 0.22% |
| 91 Days Tbill (Md 28/11/2025) | Bond - Gov't/Treasury | ₹0.99 Cr | 0.22% |
| Laxmi Dental Ltd | Equity | ₹0.98 Cr | 0.22% |
| 91 Days Tbill Red 16-10-2025 | Bond - Gov't/Treasury | ₹0.5 Cr | 0.11% |
| India (Republic of) | Bond - Short-term Government Bills | ₹0.4 Cr | 0.09% |
| 91 Days Tbill Red 23-10-2025 | Bond - Gov't/Treasury | ₹0.2 Cr | 0.05% |
Large Cap Stocks
25.15%
Mid Cap Stocks
18.55%
Small Cap Stocks
43.86%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹374.11 Cr | 84.51% |
| Basic Materials | ₹17.94 Cr | 4.05% |
| Financial Services | ₹2.24 Cr | 0.50% |
Standard Deviation
This fund
--
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better

Since February 2024

Since February 2024
Since May 2025
Since February 2024
Since January 2025
ISIN INF03VN01878 | Expense Ratio 2.38% | Exit Load 1.00% | Fund Size ₹443 Cr | Age 1 year 8 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹25,112 Cr
Address
1&2 Senapati Bapat Marg, Elphinstone Road (West) Mumbai Mumbai City, Mumbai
Your principal amount will be at Very High Risk


EquitySector - HealthcareVery High Risk
Regular
NAV (30-Oct-25)
Returns (Since Inception)
Fund Size
₹443 Cr
Expense Ratio
2.38%
ISIN
INF03VN01878
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+9.98%
+3.67% (Cat Avg.)
Since Inception
+22.24%
— (Cat Avg.)
| Equity | ₹394.28 Cr | 89.07% |
| Others | ₹48.4 Cr | 10.93% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹31.55 Cr | 7.13% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹30.71 Cr | 6.94% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹30.14 Cr | 6.81% |
| Fortis Healthcare Ltd | Equity | ₹29.6 Cr | 6.69% |
| Cipla Ltd | Equity | ₹20.17 Cr | 4.56% |
| Laurus Labs Ltd | Equity | ₹18.96 Cr | 4.28% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹18.1 Cr | 4.09% |
| Neuland Laboratories Ltd | Equity | ₹14.16 Cr | 3.20% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹14.1 Cr | 3.19% |
| Lupin Ltd | Equity | ₹13.89 Cr | 3.14% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹13.5 Cr | 3.05% |
| Sai Life Sciences Ltd | Equity | ₹12.79 Cr | 2.89% |
| Divi's Laboratories Ltd | Equity | ₹12.28 Cr | 2.77% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹10.97 Cr | 2.48% |
| Abbott India Ltd | Equity | ₹9.47 Cr | 2.14% |
| Gland Pharma Ltd | Equity | ₹8.58 Cr | 1.94% |
| Shaily Engineering Plastics Ltd | Equity | ₹8.44 Cr | 1.91% |
| Ajanta Pharma Ltd | Equity | ₹7.76 Cr | 1.75% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹7.33 Cr | 1.66% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹7.3 Cr | 1.65% |
| Mankind Pharma Ltd | Equity | ₹7.28 Cr | 1.64% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹7.12 Cr | 1.61% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹6.97 Cr | 1.58% |
| Anthem Biosciences Ltd | Equity | ₹6.68 Cr | 1.51% |
| Pfizer Ltd | Equity | ₹6.63 Cr | 1.50% |
| AstraZeneca Pharma India Ltd | Equity | ₹6.55 Cr | 1.48% |
| Alembic Pharmaceuticals Ltd | Equity | ₹6.19 Cr | 1.40% |
| Emcure Pharmaceuticals Ltd | Equity | ₹6.01 Cr | 1.36% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹5.28 Cr | 1.19% |
| Thyrocare Technologies Ltd | Equity | ₹5.27 Cr | 1.19% |
| Treasury Bills | Bond - Gov't/Treasury | ₹5 Cr | 1.13% |
| 364 DTB 18122025 | Bond - Gov't/Treasury | ₹4.94 Cr | 1.12% |
| Poly Medicure Ltd | Equity | ₹4.56 Cr | 1.03% |
| Net Receivables / (Payables) | Cash - Collateral | ₹-4.31 Cr | 0.97% |
| Acutaas Chemicals Ltd | Equity | ₹4.15 Cr | 0.94% |
| HealthCare Global Enterprises Ltd | Equity | ₹3.54 Cr | 0.80% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹3.51 Cr | 0.79% |
| Supriya Lifescience Ltd | Equity | ₹3.48 Cr | 0.79% |
| Navin Fluorine International Ltd | Equity | ₹3.33 Cr | 0.75% |
| Shilpa Medicare Ltd | Equity | ₹3.11 Cr | 0.70% |
| 182 Days Tbill Red 28-05-2026 | Bond - Gov't/Treasury | ₹2.96 Cr | 0.67% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹2.55 Cr | 0.58% |
| Zota Health Care Ltd | Equity | ₹2.49 Cr | 0.56% |
| Piramal Pharma Ltd | Equity | ₹2.27 Cr | 0.51% |
| PB Fintech Ltd | Equity | ₹2.24 Cr | 0.50% |
| Jubilant Ingrevia Ltd Ordinary Shares | Equity | ₹2.02 Cr | 0.46% |
| 364 DTB 03102025 | Bond - Gov't/Treasury | ₹2 Cr | 0.45% |
| Orchid Pharma Ltd | Equity | ₹1.99 Cr | 0.45% |
| 91 Days Tbill (Md 04/12/2025) | Bond - Gov't/Treasury | ₹1.98 Cr | 0.45% |
| OneSource Specialty Pharma Ltd | Equity | ₹1.87 Cr | 0.42% |
| 91 Days Tbill Red 30-10-2025 | Bond - Gov't/Treasury | ₹1.19 Cr | 0.27% |
| 91 Days Tbill (Md 20/11/2025) | Bond - Gov't/Treasury | ₹0.99 Cr | 0.22% |
| 91 Days Tbill (Md 28/11/2025) | Bond - Gov't/Treasury | ₹0.99 Cr | 0.22% |
| Laxmi Dental Ltd | Equity | ₹0.98 Cr | 0.22% |
| 91 Days Tbill Red 16-10-2025 | Bond - Gov't/Treasury | ₹0.5 Cr | 0.11% |
| India (Republic of) | Bond - Short-term Government Bills | ₹0.4 Cr | 0.09% |
| 91 Days Tbill Red 23-10-2025 | Bond - Gov't/Treasury | ₹0.2 Cr | 0.05% |
Large Cap Stocks
25.15%
Mid Cap Stocks
18.55%
Small Cap Stocks
43.86%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹374.11 Cr | 84.51% |
| Basic Materials | ₹17.94 Cr | 4.05% |
| Financial Services | ₹2.24 Cr | 0.50% |
Standard Deviation
This fund
--
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better

Since February 2024

Since February 2024
Since May 2025
Since February 2024
Since January 2025
ISIN INF03VN01878 | Expense Ratio 2.38% | Exit Load 1.00% | Fund Size ₹443 Cr | Age 1 year 8 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹25,112 Cr
Address
1&2 Senapati Bapat Marg, Elphinstone Road (West) Mumbai Mumbai City, Mumbai
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments